CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...
Phase 3
Madrid, Spain and 73 other locations
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...
Phase 3
Madrid, Spain and 161 other locations
the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...
Phase 3
Madrid, Spain and 36 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Madrid, Spain and 75 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
Madrid, Spain and 107 other locations
This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple...
Phase 4
Madrid, Spain and 9 other locations
This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis...
Phase 4
Madrid, Spain and 10 other locations
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...
Phase 3
Madrid, Spain and 64 other locations
study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...
Phase 3
Madrid, Spain and 40 other locations
with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...
Phase 3
Madrid, Spain and 121 other locations
Clinical trials
Research sites
Resources
Legal